Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
NLS Pharmaceutics ( (NLSP) ) has issued an update.
On October 23, 2025, NLS Pharmaceutics Ltd. and Kadimastem Ltd. announced that they received Nasdaq approval for their merger, expected to close on October 30, 2025. Following the merger, the combined entity will be named NewcelX Ltd., with Kadimastem shareholders holding 84.4% of the new company, reflecting the relative value contributions of each company. This merger is expected to enhance their market position by advancing clinical programs like AstroRx® for ALS and IsletRx for diabetes.
More about NLS Pharmaceutics
NLS Pharmaceutics Ltd. is a Swiss-based clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system disorders. Kadimastem Ltd. is a clinical-stage cell therapy company developing allogeneic cell products for neurodegenerative diseases and diabetes.
Average Trading Volume: 401,049
Technical Sentiment Signal: Sell
Current Market Cap: $7.19M
For detailed information about NLSP stock, go to TipRanks’ Stock Analysis page.